Arthneeti

Solara Active Pharma Sciences Q2 FY27 Share Price & Earnings Call Analysis

₹655.25+0.22% today
Market cap
₹3,180 Cr
P/E
67.20
ROE
-0.13%
PEG
2.75
Price to sales
2.07
Debt to equity
0.41
52W high / low
₹753 / ₹426
Sales growth (5Y)
-3.27%
EBITDA margin
15.23%
Net profit margin
-0.11%
Promoter holding
41.93%
Sales (last year)
₹1,535 Cr

Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]

Guidance scorecard · Q2 FY27 call

What Solara Active's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#30of 83 in
Pharmaceuticals & Biotechnology
Revenue20–40%MarginsFlatCapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ2 FY27 call

20–40%
  • CRAMS platform currently small but targeted for growth over the next 3-5 years; focus on building traction through services and chemistry offerings, leveraging accreditations in Japan, Brazil, U.S., Europe.
  • Immediate priority is optimizing existing products for near-term opportunities via debottlenecking, operational excellence, cash generation, and expanding market reach.
  • Base business shows good volume-driven growth; price increase contributed approx. INR 25-30 crores while volume expansion contributes the balance.
  • Gross margins expected to stabilize around 52%-55% adjusted for raw material price rises.
  • Strategic reviews, especially on ibuprofen and Vizag plant, ongoing; market dynamics and supply conditions (e.g., West Asia crisis) impact growth and profitability.

2 more points from Solara Active's call on revenue

Create a free account to keep reading this call

Full Q2 FY27 analysis

MarginsQ2 FY27 call

Flat

See what Solara Active said on margins — free account, 30 seconds.

Full Q2 FY27 analysis

CapexQ2 FY27 call

Planned
  • Solara plans close to INR 40-50 crores of annual capex, typically INR 10-15 crores spent per quarter.
  • Current capex focuses on debottlenecking and creating meaningful capacity, especially for high-margin products.
  • Investments are aimed at operational excellence, improving yields, and managing operating expenses.
  • The company is evaluating strategic options related to the Vizag facility, ibuprofen business, and CRAMS platform but has not finalized decisions.

2 more points from Solara Active's call on capex

Create a free account to keep reading this call

Full Q2 FY27 analysis

FundraisingQ2 FY27 call

See what Solara Active said on fundraising — free account, 30 seconds.

Full Q2 FY27 analysis

Order bookQ2 FY27 call

  • There is mention of ongoing production campaigns and steady demand for APIs, indicating active order flow.
  • The company has highlighted maintaining strong relationships with marquee customers and careful selection of business to ensure sticky and long-term partnerships.
  • Focus is on debottlenecking, operational excellence, and expanding the reach of existing products, which implies ongoing orders being worked upon.

2 more points from Solara Active's call on the order book

Create a free account to keep reading this call

Full Q2 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Solara Active rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Solara Active.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Solara Active

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Solara Active

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +30.49%30.49%37.27%37.27%37.23%37.94%42.01%42.01%42.00%42.00%41.93%41.93%
FIIs +16.62%15.80%14.00%14.25%14.67%14.63%14.25%13.58%11.98%11.59%11.52%10.71%
DIIs +1.75%2.97%2.83%3.37%3.19%2.61%2.62%2.69%3.64%3.75%3.74%3.89%
Public +51.14%50.73%45.89%45.11%44.92%44.82%41.10%41.71%42.37%42.66%42.79%43.46%
No. of Shareholders72,91873,91277,17071,88283,14875,79174,33472,47971,89070,40070,49070,905

Financials of Solara Active

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +425212299363347300273319314349387382417
Expenses +388374290322286243228262279312330320340
Operating Profit38-1621042615845573537586277
OPM %9%-76%3.3%12%18%19%17%18%11%11%15%16%18%
Other Income +-4-62-120101610-763-4
Interest24253131282729242122282218
Depreciation26262525252524242426262727
Profit before tax-17-275-167-1388-211-10-17101628
Tax %0%0%53%0%0%0%0%0%0%0%0%0%0%
Net Profit +-17-275-255-1388-211-10-17101628
EPS in Rs-3.58-57.36-53.20-3.742.222.24-0.582.91-2.79-4.822.653.385.86

Financials of Solara Active

Profit & Loss

Annual income statement trend

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +5211,3871,3221,6171,2681,4441,2891,2841,3691,535
Expenses +4641,1741,0621,2311,1881,3091,3841,0771,1821,301
Operating Profit5721326038681134-95206187234
OPM %11%15%20%24%6%9%-7%16%14%15%
Other Income +21227291622-18580-2
Interest2582788475901051159589
Depreciation34839410911211110399100105
Profit before tax060115222-91-45-4881-737
Tax %-70%1%0%0%-36%-50%16%0%0%
Net Profit +059115221-58-22-5671-737
EPS in Rs17.3032.0146.22-12.11-4.62-118.210.15-2.057.07
Dividend Payout %0%22%5%11%0%-49%0%0%0%

Financials of Solara Active

Balance Sheet

Capital structure and asset base

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital25262736363636404548
Reserves7399301,0591,5531,4891,4648981,0541,2081,388
Borrowings +6335387226211,0371,0131,012796687591
Other Liabilities +425466346404383386406342393427
Total Liabilities1,8211,9602,1532,6142,9452,8992,3512,2322,3332,454
Fixed Assets +1,0861,2181,3971,3821,3561,3641,2681,1931,2381,201
CWIP71404088239238256280205208
Investments1000022253
Other Assets +6637017161,1441,3501,2958257578861,043
Total Assets1,8211,9602,1532,6142,9452,8992,3512,2322,3332,454

Financials of Solara Active

Cash Flows

Operating, investing and financing cash movement

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +49166242155-242156109213153
Cash from Investing Activity +-85-113-359-106-243-81-4-37-99
Cash from Financing Activity +68-239792334-113-106-180-54
Net Cash Flow3130-20142-151-38-0-41
Free Cash Flow14108-25-16-4514669173101
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit92%85%103%49%-277%106%-113%104%83%

Financials of Solara Active

Ratios

Working capital efficiency and return ratios

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days18476631091411369993117
Inventory Days252111170149321258163185170
Days Payable420127132156154142142144146
Cash Conversion Cycle1660101102308252120134140
Working Capital Days-124-22-32163720-128-62-24
ROCE %10%12%15%-0%2%-9%6%5%

Guidance history

How Solara Active's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY27 call →20–40%FlatPlanned——
Q1 FY27 call →10–20%FlatPlanned—Rising
Q4 FY26 call →10–20%FlatNone plannedNone plannedRising
Q3 FY26 call →10–20%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

39out of 100

Momentum score · price trend

39 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+10.0%68%
Last 6 months+32.2%81%
Last 3 months+29.0%91%

The price is 60% below its all-time high of ₹1,637.51 (6 Aug 2021). Stocks more than 20% below their peak have their score halved, so 78 became 39.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Solara Active: 0.4 × 68 + 0.4 × 81 + 0.2 × 91 = 78, halved to 39 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd